Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial

Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial

Eli Lilly said orforglipron was better at lowering blood sugar levels than Novo Nordisk's oral semaglutide, and helped patients lose more weight.

Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial – DG Verifications & Stats

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024.Scott Olson | Getty Images Eli Lilly on Wednesday said its experimental pill outperformed Novo Nordisk’s own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes.  The late-stage study comes as Eli Lilly’s pill inches closer to becoming another needle-free alternative in the bloc…

Jim Cramer says Eli Lilly's obesity pill could be more of a 'lifetime drug' than shots - Daily news Update

Don’t count out Eli Lilly’s oral GLP-1 drug for obesity and diabetes just yet, according to CNBC’s Jim Cramer . That was his takeaway following the latest study involving Lilly’s orforglipron, the experimental pill that has been the subject of Wall Street debate since weight-loss data released in early August came in below investor expectations. The stock tumbled 14% in a single day as investors feared that their expectations for orforglipron sa…

Lilly’s orforglipron trumps oral semaglutide in head-to-head trial

The head-to-head trial has seen Lilly’s orforglipron come on top, beating out Novo Nordisk’s semaglutide.The post Lilly’s orforglipron trumps oral semaglutide in head-to-head trial appeared first on Clinical Trials Arena.

Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial – RamaOnHealthcare

Key Points- Eli Lilly said its experimental pill outperformed Novo Nordisk's own oral drug in the first head-to-head study comparing the two medicines in patients with Type 2 diabetes. - Eli Lilly said its pill, orforglipron, was superior at the trial's main goal of lowering blood sugar levels at 52 weeks compared to Novo Nordisk's [...]